https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=18984
No pharmaceutical opinion available for this interaction.
Rifampicin may induce the metabolism (UGT 1A1 and CYP3A) and decrease the plasma concentration of Bictegravir.
Possible decrease of clinical efficacy and risk of possible development of resistance to antiretroviral class.
Contraindicated. Use alternative.
In patients without resistance to integrase inhibitors, dolutegravir 50 mg BID or raltegravir 800 mg BID : see dolutegravir + rifampicin or raltegravir + rifampicin.
–
–
Rifabutin : see dolutegravir + rifabutin or raltegravir + rifabutin.
–
–
Reference number |
---|
# patients |
HIV |
Dose |
Frequency |
AUC |
Cmax |
3337 | 3440 |
---|---|
15 | 26 |
- | - |
75 mg * | 50 mg † |
x 1 | BID |
- 75% | - 61% |
- 28% | - 47% |
3337 | 3440 |
---|---|
15 | 26 |
- | - |
600 mg | 600 mg |
QD | QD |
Ref #3337 : * Fed.
Ref #3440 : † Administered as a fixed-dose tablet also containing emtricitabine 200mg and tenofovir alafenamide 25mg.
° Compared to standard once daily administration.
Despite the increased frequency of administration, the pharmacokinetic interaction is not counteracted.